Resultado de búsqueda
- 含uft的二联方案; irox方案 - 生物制剂的作用. 贝伐珠单抗和生物仿制药的有效性和毒性 - 与含奥沙利铂的方案联用 - 与含伊立替康的方案联用 - folfoxiri - 贝伐珠单抗一线治疗是否适合所有患者? - 不良反应 - 禁忌证; ras/braf野生型肿瘤 - 西妥昔单抗和帕尼单抗的 ...
Noticias Facultad de Medicina. Instituto Res Publica y Fundación Chile Siempre presentan libro “Aborto y Eutanasia, Dilemas sobre el Derecho a la Vida” en U. Finis Terrae. El director del Instituto de Bioética, Dr. Manuel Santos, el académico Dr. Paulo López y el decano de la […]
A mixture of uracil and tegafur (UFT) is a common antineoplastic agent in Japan. We report a 64-year-old Japanese woman with discoid lupus erythematosus (DLE)-like lesions which were induced by UFT. After surgery to treat lung cancer, UFT (300 mg/day) was administered and she developed round erythema on her right cheek.
A mixture of uracil and tegafur (UFT) is a common antineoplastic agent in Japan. We report a 64-year-old Japanese woman with discoid lupus erythematosus (DLE)-like lesions which were induced by UFT. After surgery to treat lung cancer, UFT (300 mg/day) was administered and she developed round erythema on her right cheek.
biblioteca@uft.cl. Teléfonos. Renovaciones Biblioteca Central: +56 2 24207593. Renovaciones Hemeroteca: +56 2 24207594. Bibliotecaria Referencia: +56 2 24207635. Biblioteca de Arquitectura: +56 2 24207381 / +56 2 24207382. Dirección de Biblioteca: +56 2 24207592 / +56 2 24207124.
No hand-foot syndrome grade>1 was seen. In total, 67% of eligible patients received second-line therapy. UFT plus LV with alternating irinotecan and oxaliplatin is an efficacious first-line treatment for mCRC, with minimal neurotoxicity and hand-foot syndrome. AD Department of Clinical Oncology, Christie Hospital, Manchester, UK. PMID 18682717
The present retrospective study suggests a possible efficacy of postoperative adjuvant therapy with UFT plus PSK in elderly patients over 70 years of age with resected colorectal cancer. AD Department of Surgical Oncology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Kahoku County, Ishikawa, Japan. shin-yo@kanazawa-med.ac.jp